|
|
Drugs for Stomach Carcinoma in Situ (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB): (show all 33)
| id | | Name | Status | Phase | Clinical Trials | Cas Number | PubChem Id |
|---|
| 1 | | Fentanyl | approved, illicit, investigational | Phase 3 | 705 | 437-38-7 | 3345 | 1-Phenethyl-4-(N-phenylpropionamido)piperidine 1-Phenethyl-4-N-propionylanilinopiperidine 437-38-7 5-22-08-00049 (Beilstein Handbook Reference) 80832-90-2 990-73-8 (citrate) AC1L1FQ2 Abstral Actiq BIDD:GT0555 BRN 0494484 CHEBI:119915 CHEMBL596 CID3345 D00320 DB00813 Duragesic Duragesic (TN) Duragesic-100 Duragesic-12 Duragesic-25 Duragesic-50 Duragesic-75 Durogesic EINECS 207-113-6 Fentanest Fentanil Fentanil [DCIT] Fentanila Fentanila [INN-Spanish] Fentanilo Fentanyl Fentanyl (JAN/USAN/INN) Fentanyl - Novaplus Fentanyl Citrate Fentanyl [INN:BAN] Fentanyl citrate Fentanyl-100 | Fentanyl-12 Fentanyl-25 Fentanyl-50 Fentanyl-75 Fentanylum Fentanylum [INN-Latin] HSDB 3329 IONSYS JNS020QD L001275 LS-124439 Lazanda Matrifen MolPort-003-847-369 N-(1-Phenethyl-4-piperidinyl)-N-phenylpropionamide N-(1-Phenethyl-4-piperidyl)propionanilide N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide N-(1-phenethylpiperidin-4-yl)-N-phenylpropanamide N-Phenethyl-4-(N-propionylanilino)piperidine N-Phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide NCGC00168252-01 Nasalfent Oprea1_152073 Oprea1_207148 PDSP1_000860 PDSP2_000846 Pentanyl Phentanyl Propanamide, N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)- (9CI) R 4263 Rapinyl Sentonil Sublimase Sublimaze Subsys UNII-UF599785JZ fentanyl | |
| | 2 | | Liver Extracts | | Phase 3 | 3572 | | | | 3 | | Narcotics | | Phase 3 | 2709 | | | | 4 | | pancreatic polypeptide | | Phase 3 | 20 | | | | 5 | | Analgesics | | Phase 3 | 9358 | | | | 6 | | Peripheral Nervous System Agents | | Phase 3 | 18510 | | | | 7 | | Analgesics, Opioid | | Phase 3 | 2304 | | | | 8 | | Anesthetics | | Phase 3 | 7385 | | | | 9 | | Anesthetics, General | | Phase 3 | 2274 | | | | 10 | | Central Nervous System Depressants | | Phase 3 | 10016 | | | | 11 | | Anesthetics, Intravenous | | Phase 3 | 1943 | | | | 12 | | Cola | Nutraceutical | Phase 3 | 1768 | | | | 13 | | Oxaliplatin | approved, investigational | Phase 2, Phase 1 | 1322 | 61825-94-3 | 5310940, 9887054, 6857599, 43805, 6857599, 9887054 | CHEMBL1201055 CID9887054 D01790 DACPLAT Diaminocyclohexane Oxalatoplatinum Eloxatin Eloxatin (TN) Elplat Foloxatine L-OHP | Oxalatoplatin Oxalatoplatinum Oxaliplatin Oxaliplatin (JAN/USAN/INN) Oxaliplatin [Usan:Inn:Ban] Oxaliplatino [Spanish] Oxaliplatinum [Latin] Oxaloplatine [French] Oxaloplatino [Spanish] Transplatin oxaliplatin | |
| | 14 | | Cisplatin | approved | Phase 2 | 2540 | 15663-27-1 | 84093, 441203, 2767 | (SP-4-1)-diamminedichloridoplatinum (SP-4-1)-diamminedichloroplatinum (SP-4-2)-diamminedichloridoplatinum (SP-4-2)-diamminedichloroplatinum Abiplatin Biocisplatinum Briplatin CACP CDDP CHEBI:35852 CID441203 CPD0-1392 CPDC CPDD Carboquone Cis Pt II Cis-DDP Cis-Diaminedichloroplatinum Cis-Diamminedichloroplatinum Cismaplat Cisplatin Cisplatine Cisplatino Cisplatinum Cisplatyl Citoplationo DB00515 DDP DDPT Diamminedichloroplatinum | EU-0100918 Lederplatin Neoplatin Peyrone's chloride Peyrone's salt Plastin Platamine Platiblastin Platidiam Platinex Platinol Platinol-AQ Platinol-aq Platinoxan Platinum Ammine Chloride Platinum Ammonium Chloride Platinum Diamine Dichloride Randa Trans-DDP Trans-Diaminedichloroplatinum Trans-Diamminedichloroplatinum Trans-Dichlorodiammine Platinum Trans-Platinumdiammine Dichloride cis-DDP cis-Diamminedichloroplatinum cis-Dichlorodiammineplatinum(II) cis-[PtCl2(NH3)2] cis-diamminedichloridoplatinum(II) cis-diamminedichloroplatinum(II) nchembio773-comp1 trans-diamminedichloridoplatinum(II) | |
| | 15 | | Fluorouracil | approved | Phase 1, Phase 2 | 1684 | 51-21-8 | 3385 | 1-fluoro-1h-pyrimidine-2,4-dione 1004-03-1 1upf 2,4-Dihydroxy-5-fluoropyrimidine 2,4-Dioxo-5-fluoropryimidine 2,4-Dioxo-5-fluoropyrimidine 47576_FLUKA 4921-97-5 5 FU Lederle 5 FU medac 5 Fluorouracil 5 Fluorouracil biosyn 5 HU Hexal 5-FU 5-FU (TN) 5-FU Lederle 5-FU medac 5-Faracil 5-Fluor-2,4(1H,3H)-pyrimidindion 5-Fluor-2,4(1H,3H)-pyrimidindion [Czech] 5-Fluor-2,4-dihydroxypyrimidin 5-Fluor-2,4-dihydroxypyrimidin [Czech] 5-Fluor-2,4-pyrimidindiol 5-Fluor-2,4-pyrimidindiol [Czech] 5-Fluoracil 5-Fluoracil [German] 5-Fluoracyl 5-Fluoro-2,4(1H,3H)-pyrimidinedione 5-Fluoro-2,4-pyrimidinedione 5-Fluoropyrimidin-2,4-diol 5-Fluoropyrimidine-2,4-dione 5-Fluorouracil 5-Fluorouracil-biosyn 5-Fluoruracil 5-Fluoruracil [German] 5-Fluracil 5-Ftouracyl 5-HU Hexal 5-fluoro uracil 5-fluoro-1H-pyrimidine-2,4-dione 5-fluoropyrimidine-2,4(1H,3H)-dione 5-fluorouracil 51-21-8 5FU 79108-01-3 AC-11201 AC1L1FTE AC1Q4N2X AI3-25297 AKOS000119162 AKOS003237897 AccuSite Actino-Hermal Adrucil Adrucil (TN) Allergan Brand of Fluorouracil Arumel BB_NC-0576 BSPBio_002048 C07649 C4H3FN2O2 CCRIS 2582 CHEBI:46345 CHEMBL185 CID3385 CPD0-1327 CPD000038082 CSP Brand of Fluorouracil Carac Carac (TN) Carzonal Cinco FU Cytosafe D005472 D00584 DB00544 Dakota Brand of Fluorouracil Dakota, Fluorouracile Dermatech Brand of Fluorouracil Dermik Brand of Fluorouracil DivK1c_000054 EINECS 200-085-6 EU-0100536 Effluderm Effluderm (free base) Efudex Efudix Efurix F 6627 F0151 F6627_SIGMA F8423_SIGMA FT-0082524 FU Ferrer Brand of Fluorouracil Fiverocil Fluoro Uracil Fluoro Uracile ICN Fluoro-Uracile ICN Fluoro-uracile Fluoro-uracilo Fluoroblastin Fluoroplex Fluoroplex (TN) Fluorouracil Fluorouracil (JP15/USP/INN) Fluorouracil GRY Fluorouracil Mononitrate Fluorouracil Monopotassium Salt Fluorouracil Monosodium Salt Fluorouracil Potassium Salt Fluorouracil Teva Brand Fluorouracil [USAN:INN:BAN:JAN] | Fluorouracil-GRY Fluorouracile Fluorouracile Dakota Fluorouracile [DCIT] Fluorouracilo Fluorouracilo Ferrer Far Fluorouracilo [INN-Spanish] Fluorouracilum Fluorouracilum [INN-Latin] Fluoruracil Fluouracil Flurablastin Fluracedyl Fluracil Fluracilum Fluri Fluril Fluro Uracil Fluroblastin Flurodex Flurouracil Flurox Ftoruracil Gry Brand of Fluorouracil HMS1920O18 HMS2090I04 HMS2091F19 HMS500C16 HSDB 3228 Haemato Brand of Fluorouracil Haemato fu Haemato-fu Hexal Brand of Fluorouracil I07-0022 ICN Brand of Fluorouracil IDI1_000054 IN1335 KBio1_000054 KBio2_001321 KBio2_003889 KBio2_006457 KBio3_001268 KBioGR_001253 KBioSS_001321 Kecimeton LS-153 Lopac-F-6627 Lopac0_000536 MLS000069498 MLS002415705 MolPort-000-156-102 MolPort-003-990-447 MolPort-004-758-143 MolPort-004-758-144 MolPort-005-861-486 NCGC00015442-01 NCGC00015442-03 NCGC00015442-10 NCGC00091349-01 NCGC00091349-02 NCGC00091349-03 NCGC00091349-04 NCGC00091349-05 NCGC00091349-07 NCGC00091349-08 NCI60_001652 NINDS_000054 NSC 19893 NSC-19893 NSC19893 Neocorp Brand of Fluorouracil Neofluor Onkofluor Onkoworks Brand of Fluorouracil Phthoruracil Phtoruracil Queroplex Ribofluor Riemser Brand of Fluorouracil Ro 2-9757 Ro-2-9757 Roche Brand of Fluorouracil S1209_Selleck SAM002264615 SMR000038082 SPBio_000291 SPECTRUM1500305 STK297802 Spectrum2_000076 Spectrum3_000434 Spectrum4_000557 Spectrum5_000718 Spectrum_000841 T5233394 TL8006093 Teva Brand of Fluorouracil Timazin U 8953 U-8953 UNII-U3P01618RT UPCMLD-DP130 UPCMLD-DP130:001 URF Ulup WLN: T6MVMVJ EF ZINC00897110 biosyn Brand of Fluorouracil fluorouracil inhibits thymilidate synthetase medac Brand of Fluorouracil nchembio.90-comp3 nchembio809-comp6 ribosepharm Brand of Fluorouracil tetratogen | |
| | 16 | | leucovorin | approved | Phase 1, Phase 2 | 952 | 1492-18-8 | 54575 | (6S)-5-Formyl-5,6,7,8-tetrahydrofolic acid (6S)-Folinic acid (6S)-Leucovorin (S)-Leucovorin Calcium citrovorum factor Calcium folinate Citrovorum factor Folinic acid Folinic acid calcium salt Folinic acid calcium salt USP27 Folinic acid-SF Fusilev | L-Folinic acid L-leucovorin Leucal Leucovorin Leucovorin Calcium Leucovorin calcium Leucovorin folinic acid Leucovorin sodium Leukovorin Levofolene Levofolinic acid Levoleucovorin N-[4-({[(6S)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)benzoyl]-L-glutamic acid Wellcovorin |
| | 17 | | Folic Acid | approved, nutraceutical | Phase 1, Phase 2 | 2924 | 59-30-3 | 6037 | (2S)-2-[[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid 01769_FLUKA 2d0k 33609-88-0 36653-55-1 (mono-potassium salt) 59-30-3 6484-89-5 (mono-hydrochloride salt) AC-11682 AC1L1LNX AI3-26387 AKOS000503224 ARONIS014410 Acfol (Spain) Acide folique Acide folique [INN-French] Acido folico Acido folico [INN-Spanish] Acidum folicum Acidum folicum [INN-Latin] Acifolic Antianemia factor Apo-Folic BIDD:ER0563 BIDD:GT0641 BIF0608 BPBio1_000654 BSPBio_000594 BSPBio_002338 C00504 C20H20N6O6 CAS-59-30-3 CCRIS 666 CHEBI:27470 CHEMBL1622 CID6037 CPD000471860 Cytofol D00070 DB00158 DivK1c_000494 Dosfolat B activ EINECS 200-419-0 F0043 F7876_SIAL F7876_SIGMA F8758_SIGMA F8798_SIAL F8890_SIGMA FOL Facid Factor U Folacid Folacin Folaemin Folaemin [Netherlands] Folan Folasic (Australia) Folate Folbal Folcidin Folcidin (VAN) Folcysteine Foldine Foldine [France] Folettes Foliamin Folic Folic Acid Folic acid Folic acid (JP15/USP/INN) Folic acid (TN) Folic acid [BAN:INN:JAN] Folic acid [INN:BAN:JAN] Folic acid dihydrate Folicet Folicet (TN) Folico Folico (Italy) Folina Folina (Italy) Folipac | Folsaeure Folsan Folsaure Folsav Folvite Folvron Glutamic acid, N-(p-(((2-amino-4-hydroxypyrimido(4,5-b)pyrazin-6-yl)methyl)amino)benzoyl)-, L HMS1921D20 HMS2092N17 HMS501I16 HSDB 2002 IDI1_000494 InChI=1/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s Incafolic KBio1_000494 KBio2_001861 KBio2_004429 KBio2_006997 KBio3_001558 KBioGR_002222 KBioSS_001861 Kyselina listova Kyselina listova [Czech] LS-2157 Liver Lactobacillus casei factor MLS001304016 MLS001335861 Millafol Mission prenatal Mittafol MolPort-004-285-551 N-(4-(((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzo- yl)-L-glutamic acid N-(4-((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid N-(4-{[(2-Amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid N-(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid N-(p-(((2-Amino-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid N-Pteroyl-L-glutamic acid N-[(4-{[(2-Amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid N-[4-[[(2-Amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-L-glutamic acid NCGC00016265-01 NCGC00142391-01 NINDS_000494 NSC 3073 Nifolin Nifolin [Denmark] Novofolacid Novofolacid [Canada] PGA PGA (VAN) Prestwick3_000627 Prestwick_230 PteGlu Pteroyl-L-glutamate Pteroyl-L-glutamic acid Pteroyl-L-monoglutamate Pteroyl-L-monoglutamic acid Pteroylglutamate Pteroylglutamic acid Pteroylmonoglutamate Pteroylmonoglutamic acid SAM002264616 SDCCGMLS-0066738.P001 SMP2_000137 SMR000471860 SPBio_001357 SPECTRUM1502020 Serum Folate Level Spectrum2_001459 Spectrum3_000749 Spectrum4_001751 Spectrum5_000602 Spectrum_001381 UNII-935E97BOY8 Usaf cb-13 Vitamin B11 Vitamin B9 Vitamin Bc Vitamin Be Vitamin M bmse000299 folic acid nchembio.108-comp10 |
| | 18 | | Micronutrients | | Phase 1, Phase 2 | 3901 | | | | 19 | | Levoleucovorin | | Phase 1, Phase 2 | 676 | | | | 20 | | Protective Agents | | Phase 1, Phase 2 | 5651 | | | | 21 | | Vitamins | | Phase 1, Phase 2 | 3857 | | | | 22 | | Vitamin B Complex | | Phase 1, Phase 2 | 2847 | | | | 23 | | Trace Elements | | Phase 1, Phase 2 | 3900 | | | | 24 | | Calcium, Dietary | | Phase 1, Phase 2 | 4678 | | | | 25 | | Antimetabolites | | Phase 1, Phase 2 | 9454 | | | | 26 | | Immunosuppressive Agents | | Phase 1, Phase 2 | 10422 | | | | 27 | | Antimetabolites, Antineoplastic | | Phase 1, Phase 2 | 5770 | | | | 28 | | Immunologic Factors | | Phase 1, Phase 2 | 18483 | | | | 29 | | Folate | Nutraceutical | Phase 1, Phase 2 | 2924 | | | | 30 | | Vitamin B9 | Nutraceutical | Phase 1, Phase 2 | 2924 | | | | 31 | | Folinic Acid | Nutraceutical | Phase 1, Phase 2 | 2604 | | | | 32 | | Trastuzumab | approved, investigational | | 726 | 180288-69-1 | 9903 | 180288-69-1 Anti HER2 Anti-erbB2 Monoclonal Antibody D03257 HER2 Monoclonal Antibody Herceptin | Herceptin (TN) Ig gamma-1 chain C region Trastuzumab Trastuzumab (INN) Trastuzumab (genetical recombination) Trastuzumab (genetical recombination) (JAN) trastuzumab | |
| | 33 | | Mitogens | | | 1386 | | |
Interventional clinical trials: (show all 12)
| id | Name | Status | NCT ID | Phase |
|---|
| 1 | Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain | Completed | NCT00538850 | Phase 3 | | 2 | A Study of Genomic-guided 'Standard-of-care' Chemotherapy for in Advanced Gastric Cancer Patients | Recruiting | NCT01100801 | Phase 2 | | 3 | C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer | Not yet recruiting | NCT02344810 | Phase 1, Phase 2 | | 4 | Human Epidermal Growth Factor Receptor 2 (HER-2) Status in Gastric and Gastro-Esophageal Junction (GEJ) Carcinoma | Completed | NCT02731313 | | | 5 | PCLE for the Diagnosis of Gastric Intestinal Metaplasia, Intraepithelial Neoplasia, and Carcinoma | Recruiting | NCT02515721 | | | 6 | Liquid Biopsy in Monitoring the Therapeutic Efficacy of Targeted Therapy in Advanced/Metastatic Gastric Cancer | Recruiting | NCT02610218 | | | 7 | Malignant Progression of Anal Intra-epithelial Neoplasia in a Cohort of Patients | Recruiting | NCT01877135 | | | 8 | Esophageal Cytology With FISH in Detecting Esophageal Cancer in Participants Undergoing Esophago-Gastro-Duodenoscopy or Upper Endoscopy. | Recruiting | NCT02100189 | | | 9 | Clinical Relevance of ROS (V-ros UR2 Sarcoma Virus Oncogene Homolog) Aberrations in Solid Tumours | Recruiting | NCT01596374 | | | 10 | Prognostic Value and Clinical Pathology of c-MET Expression and Amplification in Gastric Carcinoma | Active, not recruiting | NCT02002416 | | | 11 | Confocal Laser Endomicroscopy for the Diagnosis of Gastric Intestinal Metaplasia, Intraepithelial Neoplasia, and Carcinoma | Not yet recruiting | NCT01642797 | | | 12 | Pilot Study of Oral 852A for Elimination of High-Grade Dysplasia in Barrett's Esophagus | Terminated | NCT00386594 | |
|
